ACM
CSTL icon

Advisors Capital Management’s Castle Biosciences CSTL Stock Holding History

Advisors Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68M Sell
238,204
-10,172
-4% -$227K 0.06% 205
2026
Q1 		$6.1M Sell
248,376
-2,301
-0.9% -$75.4K 0.07% 193
2025
Q4 		$9.75M Sell
250,677
-3,523
-1% -$114K 0.11% 173
2025
Q3 		$5.79M Buy
254,200
+8,333
+3% +$169K 0.07% 193
2025
Q2 		$5.02M Buy
245,867
+44,180
+22% +$818K 0.07% 194
2025
Q1 		$4.04M Buy
201,687
+22,752
+13% +$563K 0.06% 207
2024
Q4 		$4.77M Buy
178,935
+11,008
+7% +$335K 0.08% 195
2024
Q3 		$4.79M Buy
167,927
+25,626
+18% +$652K 0.08% 191
2024
Q2 		$3.1M Buy
142,301
+1,186
+0.8% +$26.4K 0.05% 220
2024
Q1 		$3.13M Buy
141,115
+19,226
+16% +$418K 0.06% 219
2023
Q4 		$2.63M Buy
121,889
+4,999
+4% +$88K 0.05% 229
2023
Q3 		$1.97M Buy
116,890
+37,318
+47% +$653K 0.05% 226
2023
Q2 		$1.09M Buy
79,572
+48,513
+156% +$983K 0.03% 253
2023
Q1 		$706K Sell
31,059
-152
-0.5% -$3.71K 0.02% 265
2022
Q4 		$735K Buy
31,211
+4,316
+16% +$100K 0.02% 265
2022
Q3 		$607K Buy
26,895
+1,678
+7% +$47K 0.02% 299
2022
Q2 		$554K Buy
25,217
+7,587
+43% +$176K 0.02% 292
2022
Q1 		$791K Buy
17,630
+617
+4% +$25.5K 0.02% 264
2021
Q4 		$729K Buy
17,013
+2,901
+21% +$152K 0.02% 288
2021
Q3 		$938K Buy
14,112
+3,253
+30% +$229K 0.03% 245
2021
Q2 		$796K Buy
+10,859
New +$717K 0.03% 254

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisors Capital Management's CSTL Position: Q2 2026 in Review

Advisors Capital Management reduced its Castle Biosciences (CSTL) stake by 4.1% in Q2 2026, selling an estimated $227K and leaving 238,204 shares worth $5.68M. The position accounts for 0.06% of the portfolio, ranked #205.

Advisors Capital Management first reported a position in CSTL in Q2 2021 and has held it in 21 quarters since. The position peaked at $9.75M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Advisors Capital Management held 238,204 shares of Castle Biosciences worth $5.68M as of Q2 2026.
  • Advisors Capital Management sold 10,172 Castle Biosciences shares in Q2 2026, an estimated $227K.
  • Castle Biosciences made up 0.06% of Advisors Capital Management's portfolio in Q2 2026, its #205 holding.
  • Advisors Capital Management first reported a position in Castle Biosciences in Q2 2021 and has held it in 21 quarters since.
  • Advisors Capital Management's Castle Biosciences position peaked at $9.75M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.